Panacea Biotec Limited (NSE:PANACEABIO)
522.95
+24.90 (5.00%)
Apr 17, 2025, 3:30 PM IST
Panacea Biotec Revenue
Panacea Biotec had revenue of 1.63B INR in the quarter ending December 31, 2024, with 8.63% growth. This brings the company's revenue in the last twelve months to 5.63B, up 2.06% year-over-year. In the fiscal year ending March 31, 2024, Panacea Biotec had annual revenue of 5.59B with 21.57% growth.
Revenue (ttm)
5.63B
Revenue Growth
+2.06%
P/S Ratio
5.69
Revenue / Employee
2.91M
Employees
1,936
Market Cap
32.03B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 5.59B | 992.22M | 21.57% |
Mar 31, 2023 | 4.60B | -2.01B | -30.44% |
Mar 31, 2022 | 6.61B | 364.27M | 5.83% |
Mar 31, 2021 | 6.25B | 807.43M | 14.84% |
Mar 31, 2020 | 5.44B | 873.66M | 19.13% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 516.03B |
Divi's Laboratories | 90.78B |
Cipla | 267.20B |
Mankind Pharma | 116.41B |
Apollo Hospitals Enterprise | 211.46B |
Zydus Lifesciences | 222.47B |
Aurobindo Pharma | 309.22B |
Alkem Laboratories | 127.57B |
Panacea Biotec News
- 3 months ago - Panacea Biotec subsidiary launches baby care products under “NikoMom” brand - Business Upturn
- 4 months ago - Panacea Biotec shares hit 5% upper circuit after securing Rs 127 crore vaccine supply contract from UNICEF - Business Upturn
- 4 months ago - Panacea Biotec secures Rs 127 crore UNICEF order for bivalent oral polio vaccine - Business Upturn
- 6 months ago - Panacea Biotec aims to launch dengue vaccine in next 2-3 years - Business Upturn
- 7 months ago - Panacea Biotec secures $20 million loan from DFC for vaccine capacity expansion - Business Upturn
- 8 months ago - Panacea Biotec shares surge over 3% in intraday trading - Business Upturn
- 8 months ago - Phase-3 clinical trial of dengue vaccine starts - The Times of India
- 8 months ago - Phase three clinical trial of India's own dengue vaccine, DengiAll, initiated - The Times of India